Kimera® Labs Files First FDA Investigational New Drug (IND) Application Using XoGlo® for Treatment of ARDS Secondary to COVID-19

18-Aug-2020 11:05 AM EDT, by Kimera Labs Inc

MIRAMAR, Fla., Aug. 18, 2020 Newswise — /PRNewswire/ -- Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes.  Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigational uses. Kimera currently employs 40 PhDs, technicians and staff at its Miramar Florida 27,000 sq. ft. GMP manufacturing facility, the first and only laboratory dedicated solely to exosome R&D and production in the US. 

Exosomes have been referenced in scientific and medical publications to exhibit anti-inflammatory properties, including recently published articles on their investigational use  for the treatment of Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection. Kimera® believes that its strict donor screening practices, ultra purification methods, and current Good Manufacturing Practices (cGMPs) ensure the quality and purity of its exosome products for the intended IND clinical trial. The Company is proposing a 160 patient clinical trial in a non-hospital ambulatory setting.

"I am very proud to have overseen the development of this company from its creation without outside investment to the delivery of a robust FDA IND application, in advance of the stipulated FDA conformance May 2021 date," stated Kimera® Labs founder and CEO, Duncan Ross PhD. "Our completed IND document was a six year project that involved the input of a team of passionate scientists operating without a guidebook in a novel, constantly evolving field of virus sized particles."

Since 2016, Kimera® has invested in unrivaled in-house research and production capacity to support additional IND applications coming over the next 12 months. Kimera® employs a number of in-house laboratory assays and proprietary exosome characterization methods, including its ONI super-resolution microscope which uses Stochastic Optical Reconstruction Microscopy (STORM), to better characterize and optimize its exosome products. Jan Torres, COO of Kimera®, states that "this significant investment has allowed us to put forth what we hope to be the most well-described extracellular vesicle IND application at this time. Furthermore, we hope that these well characterized proofs will allow us to output multiple IND-approved therapeutic treatments for various afflictions within the next two years."



Filters close

Showing results

110 of 5862
Released: 23-Jun-2021 3:55 PM EDT
Cooperative Extension grant aims to vaccinate NYS’ vulnerable
Cornell University

A two-year, $200,000 grant from the USDA and the Extension Foundation to Cornell University researchers aims to help promote vaccine confidence and uptake in vulnerable communities in eight New York counties, both upstate and downstate.

Released: 23-Jun-2021 12:10 PM EDT
Phone swabs can accurately detect COVID-19
University College London

An accurate, non-invasive, and low-cost method of testing for COVID-19 using samples taken from the screens of mobile phones has been developed by a team led by UCL researchers at Diagnosis Biotech.

Newswise: NIH study suggests COVID-19 prevalence far exceeded early pandemic cases
Released: 23-Jun-2021 11:35 AM EDT
NIH study suggests COVID-19 prevalence far exceeded early pandemic cases
National Institute of Biomedical Imaging and Bioengineering

In a new study, NIH researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.

Released: 23-Jun-2021 11:25 AM EDT
Half of young adults with covid-19 have persistent symptoms 6 months after
University of Bergen

A paper published in the prestigious journal Nature Medicine on long-COVID, describes persistent symptoms six months after acute COVID-19, even in young home isolated people.

Newswise:Video Embedded covid-19-vaccine-hesitancy-dr-vin-gupta-narrates-new-american-thoracic-society-video
Released: 23-Jun-2021 9:40 AM EDT
COVID-19 Vaccine Hesitancy: Dr. Vin Gupta Narrates New American Thoracic Society Video
American Thoracic Society (ATS)

The American Thoracic Society rolls out a new video to address vaccine hesitancy and answer common questions amid the COVID-19 pandemic.

18-Jun-2021 11:00 AM EDT
Had COVID-19? One Vaccine Dose Enough; Boosters For All, Study Says
American Chemical Society (ACS)

A new study in ACS Nano supports increasing evidence that people who had COVID-19 need only one vaccine dose, and that boosters could be necessary for everyone in the future.

Released: 22-Jun-2021 5:10 PM EDT
Tecnología de inteligencia artificial y ECG puede rápidamente descartar infección por COVID-19
Mayo Clinic

La inteligencia artificial puede ofrecer un manera de determinar con exactitud que una persona no está infectada con la COVID-19. Un estudio internacional y retrospectivo descubrió que la infección por SARS-CoV-2, el virus que causa la COVID-19, provoca sutiles cambios eléctricos en el corazón. Un electrocardiograma (ECG) mediado por inteligencia artificial detecta estos cambios y puede servir como una prueba rápida y confiable para descartar la infección por COVID-19.

Released: 22-Jun-2021 4:45 PM EDT
Penn Medicine to Use $1M from City of Philadelphia for Additional Community Vaccination Clinics
Perelman School of Medicine at the University of Pennsylvania

Penn Medicine will continue its collaboration with the West and Southwest Philadelphia communities to operate a series of COVID-19 vaccine clinics in partnership with community organizations, faith-based institutions, restaurants, barbershops, and even professional sports teams thanks to $1 million in funding from the City of Philadelphia, in partnership with PMHCC.

Released: 22-Jun-2021 12:30 PM EDT
Political Variables Carried More Weight Than Healthcare in Government Response to COVID-19
Binghamton University, State University of New York

Political institutions such as the timing of elections and presidentialism had a larger influence on COVID-19 strategies than the institutions organizing national healthcare, according to a research team led by a professor at Binghamton University, State University of New York.

22-Jun-2021 12:00 PM EDT
Study Testing How Well COVID-19 Vaccine Prevents Infection and Spread of SARS-CoV-2 Among University Students Now Expands to Include Young Adults Beyond the University Setting
Covid-19 Prevention Network (CoVPN)

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

Showing results

110 of 5862